Tag Archives: Pharmacy (TRBC level 4)

Brazil has enough infection data to analyze the COVID-19 Sinovac vaccine – officials | Instant News


FILE PHOTO: A man works at the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS / Thomas Peter / File Photo

SAO PAULO (Reuters) – Brazil has gathered enough infection data from the final-stage trial of the experimental COVID-19 vaccine developed by China’s Sinovac Biotech and expects interim results on its efficiency in early December, trial organizers said on Monday.

Dimas Covas, director of the Butantan biomedical research institute which is running the final-stage trial of the Sinovac vaccine in Brazil, said it now has 74 confirmed cases among the trial participants, above the 61 initial milestones set for an interim efficiency analysis.

He said the independent committee is likely to release efficiency results in the first week of December based on its data analysis.

The news comes as Britain’s AstraZeneca Plc on Monday joined US rivals Pfizer and Moderna and Russia in announcing positive results in a landmark trial, raising hopes that the world will soon have a successful vaccine to end the pandemic.

Covas said Brazil’s health ministry now had all the information needed to include Coronavac in the national program, while São Paulo’s Health Secretary Jean Gorinchteyn expected on Monday Brazilian regulators to approve the use of Sinovac’s vaccine, CoronaVac, in January.

João Gabbardo, head of Sao Paulo’s COVID-19 contingency committee, said at the same event that he expected China’s health regulators to approve Sinovac’s CoronaVac in December, which could speed up approval in Brazil.

The Sinovac vaccine has been promoted by Sao Paulo’s governor João Doria, a move that has put him at odds with President Jair Bolsonaro who is deeply skeptical of China.

Bolsonaro has attacked the Chinese vaccine for lacking credibility and it remains unclear whether the federal government will include it in its national inoculation program.

The ministry said on Sunday that it plans to sign a non-binding letter of intent to purchase vaccines from Pfizer Inc, Bharat Biotech India, Russia’s Direct Investment Fund, Moderna Inc and Janssen, a Johnson & Johnson unit, but did not mention Sinovac’s. candidate.

Reporting by Eduardo Simoes and Anthony Boadle, written by Stephen Eisenhammer; Edited by Bernadette Baum, Miyoung Kim & Shri Navaratnam

.



image source

Brazil has enough infection data to analyze the COVID-19 Sinovac vaccine – officials | Instant News


FILE PHOTO: A man works at the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. REUTERS / Thomas Peter / File Photo

SAO PAULO (Reuters) – Brazil has gathered enough infection data from the final-stage trial of the experimental COVID-19 vaccine developed by China’s Sinovac Biotech and expects interim results on its efficiency in early December, trial organizers said on Monday.

Dimas Covas, director of the Butantan biomedical research institute which is running the final-stage trial of the Sinovac vaccine in Brazil, said it now has 74 confirmed cases among the trial participants, above the 61 initial milestones set for an interim efficiency analysis.

He said the independent committee is likely to release efficiency results in the first week of December based on its data analysis.

The news comes as Britain’s AstraZeneca Plc on Monday joined US rivals Pfizer and Moderna and Russia in announcing positive results in a landmark trial, raising hopes that the world will soon have a successful vaccine to end the pandemic.

Covas said Brazil’s health ministry now had all the information needed to include Coronavac in the national program, while São Paulo’s Health Secretary Jean Gorinchteyn expected on Monday Brazilian regulators to approve the use of Sinovac’s vaccine, CoronaVac, in January.

João Gabbardo, head of Sao Paulo’s COVID-19 contingency committee, said at the same event that he expected China’s health regulators to approve Sinovac’s CoronaVac in December, which could speed up approval in Brazil.

The Sinovac vaccine has been promoted by Sao Paulo’s governor João Doria, a move that has put him at odds with President Jair Bolsonaro who is deeply skeptical of China.

Bolsonaro has attacked the Chinese vaccine for lacking credibility and it remains unclear whether the federal government will include it in its national inoculation program.

The ministry said on Sunday that it plans to sign a non-binding letter of intent to purchase vaccines from Pfizer Inc, Bharat Biotech India, Russia’s Direct Investment Fund, Moderna Inc and Janssen, a Johnson & Johnson unit, but did not mention Sinovac’s. candidate.

Reporting by Eduardo Simoes and Anthony Boadle, written by Stephen Eisenhammer; Edited by Bernadette Baum, Miyoung Kim & Shri Navaratnam

.



image source

Brazil signed a letter of intent to purchase five COVID vaccines | Instant News


FILE PHOTOS: Medical personnel treating patients in the intensive care unit (ICU) of Nossa Senhora da Conceicao hospital, during the coronavirus disease (COVID-19) outbreak, in Porto Alegre, Brazil, 19 November 2020. REUTERS / Diego Vara / File Photo

BRASILIA (Reuters) – Brazil’s health ministry said on Sunday it would sign a non-binding letter of intent to buy a coronavirus vaccine from four companies and Russia’s state wealth fund, adding that any purchase would be subject to approval by state regulators.

According to the ministry, officials met last week with representatives of Pfizer Inc, Bharat Biotech India, Russia’s Direct Investment Fund, Moderna Inc and Janssen, a unit of Johnson & Johnson.

In a statement, the ministry said its legal and technical departments were analyzing documents presented by the five entities and determining how best to purchase the vaccine at “the right time”.

The government has a contract to guarantee access to 142,900,000 doses of the coronavirus vaccine, enough to immunize at least a third of Brazil’s population, officials said in the statement.

So far, the Brazilian federal government’s main bet is on the vaccine developed by AstraZeneca PLC, which has signed a supply contract.

In Sao Paulo, Brazil’s largest state, local authorities have signed an agreement with China Sinovac Biotech Ltd to test and produce vaccines locally. Brazilian President Jair Bolsonaro, a long-time critic of China, has dismissed the vaccine as untrustworthy, without providing evidence.

Reporting by Marcela Ayres; Written by Gram Slattery

.



image source

‘Contradictory trends’ keep some Swiss hospitals overcrowded, others have room to help | Instant News


ZURICH / JENEWA (Reuters) – First a strong cough and fever, said Roland Lerch, then sleeplessness and very weakness.

When she finally passed out and had her face bruised at home, she admitted the inevitable: Of the tens of thousands of Swiss people who tested positive for COVID-19 in the first week of November, Lerch was among the hundreds who needed hospital care, quickly.

“Without supplemental oxygen, I have trouble breathing,” he told Reuters from a Zurich University Hospital bed this week, as medics checked his blood oxygen levels.

Lerch, a systems engineer at the University of Zurich, fell ill in the banking capital of Switzerland, where the second wave of the coronavirus is less violent than elsewhere in the country.

In contrast, infection rates in Switzerland’s French-speaking region are among the highest in Europe, forcing hospitals to fly patients by helicopter to Zurich, where there is more sleeping space.

As of Friday, 27 of Freibourg’s 29 intensive care beds were occupied. Geneva hospital’s 64 ICU beds are more than two-thirds full, according to the Swiss Federal Institute of Technology.

“Time and time again, we see contradictory trends,” said Thomas Steffen, a top doctor in the city of Basel, where 46 of the 52 ICU beds were filled and 33 of 38 ventilators in use, Friday.

Zurich appears calmer, with nearly 60 of the total 226 ICU beds still available for the sickest patients – and the capacity to receive more than any other hospital.

“This solidarity, between hospitals, private clinics, the home care system, the entire health system, and today with the army … it allows us today to overcome it,” said Bertrand Levrat, director of the Geneva University Hospital.

Infections rose on Friday by 4,946, about half of last week’s level, Swiss health data showed. That brings the total to 290,601, with a death toll of 3,575.

Hospitalizations increased by 252, joining more than 3,000 others who are still recovering – or fighting for their lives.

Lerch said she never lost her taste, smell or memory, like many others, but doctors told her she was at risk for developing blood clots in her lungs.

But one thing made her feel a little better. He quickly isolated himself after realizing that he was most likely COVID-19 positive.

“I bet I didn’t infect other people,” said Lerch.

Written by John Miller, reporting by Arnd Wiegmann in Zurich and Cecile Mantovani in Geneva; Edited by Giles Elgood

.



image source

Bharat Biotech offers a potential Brazilian COVID-19 vaccine | Instant News


FILE PHOTO: A man rides his motorbike past a bus parked by Indian biotech firm Bharat Biotech outside its offices in Hyderabad, India, July 3, 2020. REUTERS / Stringer / File Photo

BRASILIA (Reuters) – Bharat Biotech India this week offered a COVID-19 vaccine to Brazil that is in its final stage of clinical trials and a possible technology transfer partnership, a company executive said on Friday.

A private pharmaceutical company based in the southern city of Hyderabad is developing a whole virion inactivated vaccine called Covaxin that could be licensed in the second quarter of 2021.

“The data looks very good in terms of both reduction and prevention of disease, and we are starting Phase 3 clinical trials this week,” Executive Director Sai Prasad told Reuters.

Bharat Biotech is currently recruiting 26,000 volunteers in India for trials and results are expected between March and April, he said.

Pfizer Inc said on Wednesday that it had offered to provide Brazil with millions of doses of the COVID-19 vaccine in the first half of 2021, amid evidence that the coronavirus is spreading faster in South America’s largest country.

Pfizer and German partner BioNTech SE report the results of recent trials showing the vaccine is 95% effective in preventing COVID-19.

Bharat Biotech representatives met this week with Brazil’s health ministry and regulatory agency officials to see what are the requirements for vaccine licensing in Brazil and whether trials should take place there as well.

“We are very open to partnerships and technology transfer,” Prasad said in an interview from Hyderabad.

Bharat Biotech has sold a Hepatitis B vaccine to Brazil and is developing another vaccine for Zika and Chicungunya that the South American country is interested in, he said.

Reporting by Anthony Boadle; Edited by Nick Macfie

.



image source